Title: Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries
Authors: Ament, A ×
Baltussen, R
Duru, G
Rigaud-Bully, C
de Graeve, D
Ortqvist, A
Jönsson, B
Verhaegen, Jan
Gaillat, J
Christie, P
Cifre, A S
Vivas, D
Loiseau, C
Fedson, D S #
Issue Date: Aug-2000
Series Title: Clinical Infectious Diseases vol:31 issue:2 pages:444-50
Abstract: Pneumococcal vaccination of older persons is thought to be cost-effective in preventing pneumococcal pneumonia, but evidence of clinical protection is uncertain. Because there is better evidence of vaccination effectiveness against invasive pneumococcal disease, we determined the cost-effectiveness of pneumococcal vaccination of persons aged > or =65 years in preventing hospital admission for both invasive pneumococcal disease and pneumococcal pneumonia in 5 western European countries. In the base case analyses, the cost-effectiveness ratios for preventing invasive disease varied from approximately 11,000 to approximately 33,000 European currency units (ecu) per quality-adjusted life year (QALY). Assuming a common incidence (50 cases per 100,000) and mortality rate (20%-40%) for invasive disease, the cost-effectiveness ratios were <12,000 ecu per QALY in all 5 countries. For preventing pneumococcal pneumonia, vaccinating all elderly persons would be highly cost-effective to cost saving. Public health authorities should consider policies for encouraging pneumococcal vaccination for all persons aged > or =65 years.
ISSN: 1058-4838
Publication status: published
KU Leuven publication type: IT
Appears in Collections:Laboratory of Clinical Bacteriology and Mycology
× corresponding author
# (joint) last author

Files in This Item:

There are no files associated with this item.

Request a copy


All items in Lirias are protected by copyright, with all rights reserved.

© Web of science